Semax
Semax is a Russian-developed ACTH 4-7 + PGP heptapeptide with the strongest human signal in post-stroke recovery, including a 110-patient Gusev et al. 2018 study and older Gusev et al. 1997 clinical report, but no eligible recent Western RCT or meta-analysis was found.
Semax scored 5.8 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Peptide.
What It Is
Semax is a synthetic neuropeptide derived from the ACTH 4-7 fragment with a Pro-Gly-Pro extension added for stability. It was developed in the Soviet and Russian peptide-pharmacology ecosystem and is best known outside Russia as an intranasal nootropic for focus, memory, and neuroprotection, though its registered medical use is regional rather than global.
Mechanistically, Semax is most interesting because it can upregulate BDNF and TrkB signaling in the hippocampus in animal work, especially Dolotov et al. 2006. That gives Semax a more coherent neuroplasticity story than many peptide nootropics. The strongest accessible human evidence is not a Western healthy-adult cognition trial, though. It is Russian and post-Soviet stroke and rehabilitation literature, including Gusev et al. 2018 and Gusev et al. 1997.
The practical takeaway: Semax is a credible but under-replicated neuropeptide. It has better mechanistic and regional clinical support than many gray-market research compounds, but the 2026 audit found no eligible recent Semax RCT, systematic review, meta-analysis, or Cochrane review with at least 100 human participants. U.S. use also carries quality and regulatory uncertainty, since the FDA UNII listing identifies the substance but does not approve it as a drug.
Terminology
- ACTH: Adrenocorticotropic hormone. Semax is derived from the ACTH 4-7 fragment, not full ACTH.
- BDNF: Brain-derived neurotrophic factor. A protein that supports neuron survival, synaptic plasticity, learning, and memory.
- NGF: Nerve growth factor. A neurotrophin involved in neuron survival and repair.
- TrkB: The main receptor for BDNF. TrkB activation is one route through which BDNF affects synaptic plasticity.
- PGP: Pro-Gly-Pro. The tripeptide extension added to ACTH 4-7 to create Semax and improve peptide stability.
- BBB: Blood-brain barrier. The selective barrier that limits what enters brain tissue from blood.
- Intranasal delivery: Nasal administration. Peptides may reach the nervous system partly through olfactory and trigeminal pathways.
- Melanocortin receptors: A receptor family involved in energy balance, inflammation, stress, and neural signaling. Semax appears to have low-affinity activity here.
- Prolyl endopeptidase: An enzyme that breaks down certain neuropeptides, including enkephalins.
- Enkephalins: Endogenous opioid peptides involved in pain, reward, and stress signaling.
- RCT: Randomized controlled trial. A study design that randomly assigns participants to intervention or control.
- WADA S0: World Anti-Doping Agency category for non-approved pharmacological substances. This can matter even when a substance is not named directly.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 3 routes and 3 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Intranasal spray (0.1% - nootropic) | Nasal spray solution | Not established in Western healthy-adult RCTs; Russian and community nootropic references commonly use 300-600 mcg/day | 300-1000 mcg/day, usually 1-3 sprays per nostril, 1-2x daily |
| Intranasal spray (1% - Russian clinical) | Higher-concentration nasal spray solution | Used in Russian medical contexts for ischemic stroke, transient ischemic attack, and optic-nerve indications under physician supervision | Rarely used outside clinical settings because it is much stronger than 0.1% nootropic spray |
| Subcutaneous injection | Lyophilized powder reconstituted in bacteriostatic water | Not established for Western clinical use | Less common in community use; often discussed around 200-600 mcg per injection |
Protocols
Standard nootropic cycle Anecdotal
- Dose
- 300-600 mcg/day of 0.1% spray
- Frequency
- Once or twice daily, morning preferred
- Cycling
- 1-2 weeks on / 1 week off (community-derived)
- Duration
- 1-2 week cycles
Community pattern: 1-2 weeks on, 1 week off. No clinical trial establishes this cycle length.
Higher-end nootropic trial Anecdotal
- Dose
- 600-1000 mcg/day of 0.1% spray
- Frequency
- Split morning and early afternoon
- Duration
- Short trial only, with sleep and anxiety monitoring
Higher-frequency use increases the chance of restlessness or sleep disruption in sensitive users.
Russian stroke rehabilitation context Clinical
- Dose
- 1% intranasal Semax under clinician direction
- Frequency
- Medical-supervision schedule
- Duration
- Short clinical course in Russian neurological practice
Human stroke evidence includes [Gusev et al. 2018](https://pubmed.ncbi.nlm.nih.gov/29798983/) and [Gusev et al. 1997](https://europepmc.org/article/med/11517472), but this is not a self-directed nootropic protocol.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
Upside contribution: 3.05
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.3 | 0.825 | |
| Breadth of Benefits | 15% | 3.5 | 0.525 | |
| Evidence Quality | 25% | 2.5 | 0.625 | |
| Speed of Onset | 10% | 4.0 | 0.400 | |
| Durability | 10% | 2.5 | 0.250 | |
| Bioindividuality Upside | 15% | 2.8 | 0.420 | |
| Total | 3.045 |
Upside Rationale
Semax has real upside when the use case matches its best evidence, especially around cognition focus, neuroprotection, memory, stress resilience. Dolotov 2006 and Tsai 2007 support the main positive signal, but the useful part is not the headline mechanism. It is the chance to connect Semax to a measurable outcome and see whether the expected change appears. The upside is strongest for users with the relevant baseline problem, weaker for optimized users chasing a vague edge, and most honest when paired with tracking. For this report, Semax earns credit for plausible mechanisms, human or clinical anchors where available, and practical fit. The right read is targeted use, not automatic daily inclusion.
Efficacy (3.3/5.0): Semax has a moderate efficacy signal, strongest for neurorecovery rather than healthy nootropic use. Gusev et al. 2018 reported that Semax plus rehabilitation increased plasma BDNF and improved Barthel and motor-recovery measures in 110 post-ischemic-stroke patients. Gusev et al. 1997 also supports acute-stroke recovery direction. For healthy cognition, Asmarin et al. 1997 and Kaplan et al. 1996 point toward attention and short-term-memory effects, but those studies are smaller, older, and not independently replicated in Western populations. That keeps efficacy above average but far from a strong clinical rating.
Breadth of Benefits (3.5/5.0): Semax touches cognition, focus, memory, neuroprotection, ischemic-stroke recovery, optic-nerve practice in Russia, hypoxia-stress resilience, pediatric ADHD speculation, and possible mood or anxiety effects. The strongest lanes are neuroprotection and cognition because they connect human stroke literature with animal hippocampal BDNF work from Dolotov et al. 2006. Breadth is real, but the confidence differs sharply by endpoint. Mood, anxiety, pediatric use, and optic-nerve use are much weaker than the neurorecovery and mechanistic claims.
Evidence Quality (2.5/5.0): Semax evidence quality is capped by geography, age, and authority gaps. Animal evidence is coherent: Medvedeva et al. 2014 and Filippenkov et al. 2020 support ischemia-related immune, vascular, and transcriptomic mechanisms. Human evidence includes Russian clinical work, but no Cochrane review, AHA/ASA guideline, AAN guideline, NICE guidance, or FDA approval supports routine clinical use. The audit found no eligible recent modern human review or large RCT. That means Semax stays in the "interesting but under-replicated" bucket.
Speed of Onset (4.0/5.0): Semax is fast for an intervention in this category. Intranasal users commonly report focus or mental-energy effects within 30-60 minutes, with a peak window around 1-3 hours. That timeline fits intranasal delivery and the short plasma half-life usually cited for peptide use. Neurotrophic effects are slower: if BDNF-related changes seen in Dolotov et al. 2006 translate to humans, they would likely require repeated dosing over days to weeks. The acute score is high; the cumulative human proof remains limited.
Durability (2.5/5.0): Semax durability is modest because the acute cognitive effect fades quickly and human longitudinal data is thin. Single-dose benefits, when they occur, behave more like a short-acting nootropic than a durable training adaptation. Animal BDNF and ischemia models suggest repeated dosing could produce longer-lasting neuroplastic changes, but that has not been shown with human imaging, cognitive follow-up, or validated biomarkers. In practice, benefits appear to depend on continued or repeated use, and stopping usually means returning toward baseline within days.
Bioindividuality (2.8/5.0): Semax response varies widely. Intranasal absorption depends on nasal anatomy, mucus clearance, spray technique, mucosal inflammation, and product formulation. Subjective response also likely depends on baseline arousal, anxiety tendency, cholinergic tone, sleep quality, and neurological status. Some users report crisp focus; others report nothing or mild restlessness. No verified responder-stratification data exists, and no commercial biomarker can predict who benefits. That uncertainty is why the score stays below 3.0 despite a coherent mechanism.
Downside contribution: 2.24 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 2.0 | 0.600 | |
| Side Effect Profile | 15% | 1.8 | 0.270 | |
| Financial Cost | 5% | 2.0 | 0.100 | |
| Time/Effort Burden | 5% | 2.0 | 0.100 | |
| Opportunity Cost | 5% | 1.8 | 0.090 | |
| Dependency / Withdrawal | 15% | 1.5 | 0.225 | |
| Reversibility | 25% | 1.2 | 0.300 | |
| Total | 1.685 | |||
| Harm subtotal × 1.4 | 1.953 | |||
| Opportunity subtotal × 1.0 | 0.290 | |||
| Combined downside | 2.243 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.903 |
Downside Rationale
Semax's downside is the gap between plausible benefit and the cost, risk, or uncertainty required to test it. Dolotov 2006 and Tsai 2007 frame the caution side better than mechanism talk alone. The main issue may be safety, supervision, legality, product quality, opportunity cost, or simply weak evidence outside the best-matched population. Semax deserves extra caution when users are pregnant, medically complex, competing under drug rules, taking interacting medications, or trying to replace proven care. The practical orientation is simple: start with the lowest-risk version of the intervention, keep the trial time-bound, and stop when side effects, unclear benefit, or better alternatives show up. Dolotov 2006 is the cleanest anchor here: verified PMID; supports BDNF / TrkB mechanistic rationale and conditioned-learning signal in rats.
Safety risk (2.0/5.0): Semax has low known intrinsic safety risk but incomplete long-term certainty. Published Russian reports do not show a clear serious-harm pattern, and Gusev et al. 2018 supports tolerability in a supervised post-stroke context. The concern is not a known severe toxicity profile. The concern is missing Western pharmacovigilance, no FDA-approved product, gray-market purity variability, and unresolved U.S. compounding status in FDA safety-risk materials.
Side effect profile (1.8/5.0): Semax side effects are usually mild and administration-related. Nasal irritation is the most obvious issue because the common route is intranasal. Headache, restlessness, irritability, fatigue, and sleep disruption show up in community and clinical discussions, especially with higher or late-day dosing. Gastrointestinal effects are not a major pattern because Semax is not typically taken orally. The side-effect score stays low, but not minimal, because sensitive users can experience activating effects and because long-term surveillance is weak.
Financial cost (2.0/5.0): Semax is moderately expensive rather than prohibitive. Research-grade 0.1% nasal sprays commonly cost more than basic supplements but less than many prescription peptides or clinic-based therapies. The real cost issue is quality uncertainty. A cheap vial with poor purity, weak concentration, or bad storage can be wasted spend and potential risk. Since there is no FDA-approved U.S. product standard, vendor selection becomes part of the economic burden. That keeps cost at 2.0 instead of 1.0.
Time / effort burden (2.0/5.0): Semax is easy to administer. A typical nootropic protocol is a nasal spray once or twice daily and takes under two minutes. The friction comes from refrigeration, cycle tracking, dose timing, and avoiding late-day use if sleep is sensitive. Reconstituting lyophilized powder adds more complexity and sterility responsibility, especially for injection routes. Compared with device protocols or lifestyle interventions, Semax has low effort. Compared with an oral capsule, it is more fiddly.
Opportunity cost (1.8/5.0): Semax does not crowd out the foundational cognitive interventions: sleep, exercise, protein intake, creatine, sunlight, meditation, and skill practice. It also stacks mechanistically with many nootropic categories because it is not simply another stimulant. The opportunity cost comes from attention and risk budget. Users chasing gray-market peptides may skip better-validated cognitive basics or delay medical care for neurological symptoms. Used as an add-on after foundations, opportunity cost is low.
Dependency / withdrawal (1.5/5.0): Semax has no documented withdrawal syndrome, no known receptor downregulation pattern, and no strong community signal of escalating tolerance across typical short cycles. The common 1-2 weeks on and 1 week off pattern is precautionary rather than evidence-based. Stopping generally means the acute focus effect disappears, not that the user rebounds below baseline. Dependence risk is lower than stimulants, benzodiazepines, nicotine, or sleep drugs. The main dependency risk is psychological attachment to another productivity tool.
Reversibility (1.2/5.0): Semax is highly reversible in ordinary use. Stop the spray and acute cognitive or arousal effects should clear as the compound leaves the system. No taper is known to be required. Any BDNF-related adaptation, if it occurs in humans, would be expected to normalize rather than lock in a harmful state. Reversibility is not scored at 1.0 only because long-term human data remains incomplete and because gray-market product quality can introduce risks not inherent to Semax itself.
Verdict
Semax is a 5.8/10 fit for people considering cognition focus, neuroprotection, memory, stress resilience, with the strongest case in the populations already represented by the evidence rather than broad wellness use. Dolotov 2006 and Tsai 2007 give the report its main anchors, while the score stays worth trying because benefits are context-dependent and the evidence still leaves responder, dose, and long-term questions open. Semax makes the most sense when the target is concrete, such as a lab marker, symptom pattern, training limitation, or recovery bottleneck. It makes less sense as a background habit taken on faith. In practice, treat Semax as a tracked experiment: define the outcome first, watch for tradeoffs, and let the response decide whether it earns a place.
✅ Best for: Semax is best for experienced nootropic users who want a fast-acting focus experiment with more mechanistic depth than most gray-market peptides; adults interested in neuroprotection who understand the difference between Russian clinical signals and Western guideline-grade proof; researchers or clinicians in countries where Semax is legally available; and older adults exploring post-stroke or neurorecovery-adjacent interventions with medical supervision. It is most defensible when used after sleep, exercise, nutrition, and baseline cognitive-health work are already handled.
❌ Avoid if: Avoid Semax during pregnancy or breastfeeding, with seizure history, high baseline anxiety, unstable psychiatric symptoms, MAOI use, or psychiatric medications unless a clinician clears it. Avoid it if you need an FDA-approved, guideline-endorsed intervention for stroke, cognitive decline, ADHD, depression, or TBI. Athletes should treat Semax as anti-doping-risky because WADA S0 can apply to non-approved pharmacological substances. Also avoid if you are unwilling to accept gray-market purity and import-law uncertainty.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Cognition / Focus: 6.5/10
Score: 6.5/10Semax earns 6.5/10 for cognition focus; this is a targeted fit score. The best human cognitive signal is Russian attention and operative-memory work, including Asmarin et al. 1997 and Kaplan et al. 1996, plus strong animal learning data from Dolotov et al. 2006. That makes Semax more defensible when cognition focus is a real bottleneck and less compelling when basics already cover the same ground.
Neuroprotection: 6.5/10
Score: 6.5/10Semax gets 6.5/10 for neuroprotection; the evidence supports a narrow read. Semax has the strongest classification as a neuroprotective peptide: Gusev et al. 2018 reported BDNF and rehabilitation signals after ischemic stroke, supported by preclinical ischemia transcriptomics in Filippenkov et al. 2020. That makes Semax more defensible when neuroprotection is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the neuroprotection marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Memory: 6.0/10
Score: 6.0/10For memory, Semax lands at 6.0/10 because context matters. Memory support is strongest in animal models: Dolotov et al. 2006 found hippocampal BDNF and TrkB changes with conditioned-learning effects, while Ellis et al. 2020 supports hypoxia-stress memory protection in rats. That makes Semax more defensible when memory is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the memory marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Neuroplasticity: 6.0/10
Score: 6.0/10The neuroplasticity score is 6.0/10, and Semax needs careful framing. The neuroplasticity score rests on Dolotov et al. 2006, which found BDNF and TrkB upregulation in rat hippocampus after intranasal Semax, not on direct human neuroplasticity biomarkers. That makes Semax more defensible when neuroplasticity is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the neuroplasticity marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Geriatric / Aging Population: 5.0/10
Score: 5.0/10For readers prioritizing geriatric, Semax scores 5.0/10 today. Older adults are the most clinically relevant population because Semax evidence concentrates around stroke and neurorecovery, including Gusev et al. 2018, but Western geriatric guidance is absent. That makes Semax more defensible when geriatric is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the geriatric marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
| Use Case | Score | Summary |
|---|---|---|
| ○ Stress / Resilience Primary | 4.0 | Hypoxia and metabolic-stress animal models support a stress-resilience angle, especially Ellis et al. 2020, but human stress, cortisol, HRV, and resilience endpoints are absent. |
| ○ Nerve Regeneration | 4.5 | Russian optic-nerve use and preclinical neural protection make nerve repair a plausible research direction, but human nerve-regeneration trials remain limited. |
| ○ Flow State / Peak Mental Performance | 4.5 | Acute focus and mental-energy reports can map to flow-state use, but no formal flow, task-immersion, or performance psychology measurement exists for Semax. |
| ○ Traumatic Brain Injury | 4.5 | TBI relevance comes from overlapping neuroprotection, BDNF, and ischemia-stress mechanisms, not from a dedicated traumatic-brain-injury RCT. |
| ○ Reaction Time / Coordination | 4.0 | Acute attention and information-processing reports from Russian human work suggest possible reaction-time relevance, but no verified reaction-time RCT establishes the effect. |
| ○ Healthspan | 4.0 | Cognitive preservation and stroke-recovery mechanisms are healthspan-relevant, especially in older adults, but the human evidence remains geographically narrow. |
| ○ Energy / Fatigue | 4.0 | Acute mental energy is one of the more common community-reported benefits, but no formal fatigue, vitality, or mental-energy endpoint trial verifies the effect. |
| ○ Eye / Vision Health | 3.5 | Russian clinical use includes optic-nerve indications, but accessible verified evidence remains limited and does not reach Western ophthalmology guideline strength. |
| ○ Mood / Emotional Regulation | 3.5 | Mood-lift reports exist, and BDNF mechanisms are relevant to mood biology, but Semax has no controlled human mood trial and should not be positioned as an antidepressant. |
| ○ Anxiety | 3.5 | Anxiety signal is mixed: some users report calm focus, others report restlessness. No controlled human anxiety trial supports Semax for generalized anxiety or panic symptoms. |
| ○ Longevity / Lifespan | 3.5 | Neuroprotection is longevity-adjacent, but Semax has no lifespan, all-cause mortality, dementia-prevention, or long-term healthspan trial. |
| ○ Creativity / Divergent Thinking | 3.0 | Any creativity effect is indirect through focus, memory, or mood. No divergent-thinking, creative-output, or ideation study supports Semax. |
| ○ Anti-Inflammatory | 3.0 | Post-ischemic immune and inflammatory gene-expression effects appear in Medvedeva et al. 2014, but Semax is not a primary anti-inflammatory intervention for systemic conditions. |
| ○ Pediatric Use | 3.0 | Tsai 2007 discusses ADHD and Rett syndrome potential, but it is hypothesis-level support rather than pediatric clinical validation outside Russian practice. |
Frequently Asked Questions
How does Semax work in the brain?
Semax appears to work mainly through neurotrophic and peptide-signaling pathways. Dolotov et al. 2006 found BDNF and TrkB upregulation in rat hippocampus after intranasal Semax. It may also affect cholinergic signaling, low-affinity melanocortin receptors, and enkephalin-degrading enzymes. That supports the cognitive and neuroprotective rationale, but most mechanism data is animal or lab-based.
What does the human evidence actually show for Semax?
The strongest accessible human evidence is Russian and post-Soviet neurological research, not Western nootropic research. Gusev et al. 2018 reported BDNF and rehabilitation improvements in 110 post-ischemic-stroke patients, while Gusev et al. 1997 supports an earlier acute-stroke signal. Healthy-adult cognition claims rely more on smaller Russian attention studies and animal data.
How much Semax should I take and when?
For nootropic use, the common community range is 300-1000 mcg/day of 0.1% intranasal spray, usually taken in the morning or split morning and early afternoon. A cautious entry is 300-600 mcg/day. The higher 1% formulation belongs in Russian clinical contexts, not self-directed nootropic experimentation. The common 1-2 weeks on and 1 week off cycle is community-derived, not trial-proven.
Is Semax safe, and are there known side effects?
Semax appears to have a mild short-term side-effect profile in published Russian reports, but long-term safety is not well mapped. Reported issues include nasal irritation, headache, restlessness, sleep disruption, and occasional irritability. The bigger practical safety issue outside Russia is product quality: no FDA-approved Semax product exists, and FDA compounding materials show regulatory uncertainty.
Who should avoid Semax?
Avoid Semax during pregnancy and breastfeeding because safety data is absent. Also avoid unsupervised use with seizure history, high baseline anxiety, MAOIs, psychiatric medications, or unstable neurological disease. Athletes should be cautious: Semax is not clearly named on the the WADA Prohibited List, but WADA S0 can cover non-approved pharmacological substances.
What is the evidence gap between Russian and Western research on Semax?
The evidence gap is the central Semax issue. Semax was developed in the Soviet and Russian research ecosystem, and most human studies remain Russian-language, regionally indexed, or difficult for Western clinicians to audit. A recent evidence audit found no eligible recent Semax RCT, systematic review, meta-analysis, or Cochrane review with at least 100 human participants.
How fast does Semax work, and how long do effects last?
Semax is usually reported as fast-acting when used intranasally. Users commonly notice effects within 30-60 minutes, with a 1-3 hour functional window. That timing fits intranasal delivery and short peptide kinetics. The possible BDNF-related effects are slower and cumulative, but human evidence has not proven durable neuroplastic changes after stopping.
What is the legal status of Semax outside Russia?
Semax is registered as a medicine in Russia but is not FDA-approved as a U.S. drug or dietary supplement. The FDA UNII listing identifies the substance, but that is not approval. In the U.S., EU, and UK, Semax is generally sold as a research compound, with possible import and compounding restrictions depending on jurisdiction.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| First Western RCT in healthy adults confirms cognitive benefit | Evidence 2.5 to 3.5; Bioindividuality 2.8 to 3.2 | 6.4 / 10 💪 Strong recommend |
| Long-term BDNF durability confirmed in humans | Durability 2.5 to 3.5; Efficacy 3.3 to 3.8 | 6.4 / 10 💪 Strong recommend |
| Serious safety signal emerges in post-market surveillance | Safety 2.0 to 3.5 | 5.6 / 10 👍 Worth trying |
| Russian evidence base is retracted or severely discredited | Evidence 2.5 to 1.8 | 5.9 / 10 👍 Worth trying |
| Mega-trial confirms cognitive and neuroprotective benefit with responder data | Efficacy 3.3 to 4.0; Breadth 3.5 to 4.0; Evidence 2.5 to 3.2; Bioindividuality 2.8 to 3.5 | 6.6 / 10 💪 Strong recommend |
| FDA approval in the U.S. standardizes quality and access | Cost 2.0 to 1.5; Bioindividuality 2.8 to 3.5 | 6.3 / 10 👍 Worth trying |
Key Evidence Sources
- Dolotov OV et al. 2006 - Semax affects BDNF and trkB expression in rat hippocampus, Brain Research. Verified PMID; supports BDNF / TrkB mechanistic rationale and conditioned-learning signal in rats
- Tsai SJ 2007 - Semax, an ACTH analogue, may have therapeutic potential for ADHD and Rett syndrome, Medical Hypotheses. Verified PMID; hypothesis-level therapeutic rationale, not clinical proof
- Asmarin IP et al. 1997 - Nootropic analog of adrenocorticotropin 4-10 Semax, Zh Vyssh Nerv Deiat Im I P Pavlova. Verified PMID; supports attention and operative-memory direction, with numbers not independently verified
- Kaplan AY et al. 1996 - Effects of Semax on human attention and memory, Neuroscience Research Communications. Verified DOI; small human nootropic-like activity signal, no PMID found
- Ellis BL et al. 2020 - Protection of episodic memory by Semax in hypoxic-exposed Sprague Dawley rats, American Journal of Biomedical Science & Research. Verified DOI; animal-only hypoxia and novel-object-recognition memory support
- Gusev EI et al. 2018 - Semax in combination with rehabilitation in post-ischemic stroke patients, Zh Nevrol Psikhiatr Im S S Korsakova. Verified PMID; 110 post-stroke patients, BDNF and rehabilitation outcome direction
- Gusev EI et al. 1997 - Semax in acute ischemic stroke, Zh Nevrol Psikhiatr Im S S Korsakova. Verified PMID through Europe PMC; 30 Semax patients versus 80 controls in acute ischemic stroke context
- Miasoedova NF et al. 1999 - Semax and inflammatory response in acute ischemic stroke, Zh Nevrol Psikhiatr Im S S Korsakova. Verified PMID from audit; abstract-level support for anti-inflammatory post-ischemic response
- Medvedeva EV et al. 2014 - Semax influences immune and vascular gene expression after focal cerebral ischemia, BMC Genomics. Verified PMID and PMCID PMC3987924; rat transcriptomic mechanism support
- Filippenkov IB et al. 2020 - Protective properties of Semax after cerebral ischemia-reperfusion in rats, Genes. Verified PMID and PMCID PMC7350263; preclinical transcriptomic support
- FDA UNII Semax - Substance Registration System entry. Authority source; identifies substance but does not indicate FDA drug approval
- FDA - Certain bulk drug substances for use in compounding may present significant safety risks. Authority source; relevant to U.S. compounding-policy caution
- FDA 2026 - 503A bulks update PDF. Authority source; April 2026 update indicates Semax removal from Category 2 after nomination withdrawal and future PCAC discussion
- WADA 2026 - Prohibited List. Authority source; Semax not explicitly named in audit search, but S0 catch-all risk remains relevant
- WADA - What is prohibited. Authority source; explains S0 non-approved substance category
- Outliyr - Nootropic brain peptides Semax section. Recovered Outliyr Semax citation trail used during audit because v0.x report source was not retrievable
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Low
Citations: Dolotov 2006, Asmarin 1997, Kaplan 1996, Gusev 2018, Gusev 1997, Medvedeva 2014, Filippenkov 2020, Ellis 2020
Pre-RCT-Era Pharmacology and Use
Confidence: Limited
Citations: Asmarin 1997, Kaplan 1996, Gusev 1997, Gusev 2018, FDA 2026
Traditional Medicine Systems
Confidence: Low
Holistic Evidence for Semax
The lenses agree on one point: Semax is a neuroactive peptide with a longer Russian clinical history than most gray-market nootropics. They diverge on certainty. Mechanistic and regional clinical evidence support a real signal, while traditional evidence is essentially absent and Western authority signals are weak. Honest synthesis: Semax is worth trying only for users comfortable with an evidence silo, sourcing uncertainty, and the lack of U.S. or EU guideline support.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Cortisol AM Baseline (pre-protocol) During | Expected Watch
- hs-CRP During | Expected Stable
Pulse Dimensions to Watch
- Drive During | Expected Up | Primary
- Energy During | Expected Up | Secondary
- Calm During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- Focus Scale 1-5 | During | Expected Up
- Irritability Scale 1-5 | During | Expected Watch
- Sleep Disruption Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Severe agitation or insomnia
- Nasal irritation or infection symptoms
Other interventions for Cognition & Focus
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.045 − 0.903 = 1.142
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (1.142 / 5) × 5 = 6.1 / 10
